On June 26, 2024, the Oregon Prescription Drug Affordability Board (PDAB) voted to pause all ongoing drug reviews for the remainder of the year and postpone additional reviews until 2025. This decision, proposed by Oregon Board Chair Shelley Bailey, aims to address issues that have arisen during this year’s drug review process. These include the need for better data to determine drug net prices and to define affordability more effectively for patients and the state. Oregon’s decision to postpone the drug reviews acknowledges these unintended consequences, reflecting a cautious approach to addressing issues within the drug review process. Learn more about the Challenges and Alternatives to PDABs here.
Last Updated on July 1, 2024 by Aimed Alliance
